Stefano Molica

Stefano Molica

Catanzaro, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 204 publications

Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia: Insights From EHA 2026.

Navigating the Paradigm Shift in Chronic Lymphocytic Leukemia: Insights From EHA 2026.

Journal: European journal of haematology
Published: July 22, 2026

Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia.

Embedding cardiovascular risk assessment into routine BTK inhibitor management in chronic lymphocytic leukemia.

Journal: Expert review of hematology
Published: July 03, 2026

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma
Published: June 21, 2026

Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship Perspective.

Polypharmacy in Chronic Lymphocytic Leukemia in the Era of Targeted Agents: A Medication Stewardship Perspective.

Journal: European journal of haematology
Published: June 03, 2026

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis.

Journal: Experimental hematology & oncology
Published: May 15, 2026

Surrogate Endpoints in CLL: From Promise and Pitfalls to a Context-Specific Validation Framework.

Surrogate Endpoints in CLL: From Promise and Pitfalls to a Context-Specific Validation Framework.

Journal: Hematology reports
Published: May 12, 2026

Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta-Analysis.

Cardiovascular Safety Across Leading BTK Inhibitors in Relapsed/Refractory CLL: Results of a Network Meta-Analysis.

Journal: European journal of haematology
Published: April 09, 2026

Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomes.

Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomes.

Journal: Expert review of hematology
Published: March 17, 2026

Indirect comparison of continuous and time‑limited BTKi-venetoclax in TP53‑wild‑type CLL: does IGHV still matter?

Indirect comparison of continuous and time‑limited BTKi-venetoclax in TP53‑wild‑type CLL: does IGHV still matter?

Journal: Leukemia & lymphoma
Published: March 04, 2026

Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks.

Bridging Trials and Real Life in Fixed-Duration BTKi-Venetoclax for CLL: A Delphi-Enhanced Synthesis Incorporating Artificial Intelligence (AI) Benchmarks.

Journal: European journal of haematology
Published: February 25, 2026

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.

Journal: European journal of haematology
Published: January 21, 2026

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Journal: Cancers
Published: January 08, 2026
Showing 1-12 of 204

Last Updated: 09/26/2026